Christian Girard

Christian Girard, MiM, is a seasoned strategy consultant specializing in value creation within the orphan drug sector.

With a background in business studies from ESCP-Europe and over 25 years of experience in the life science industry, Christian's journey began in 1994 at a US medtech manufacturer's French subsidiary, later acquired by Genzyme.

During his tenure at Genzyme until 2002, he held various sales and marketing positions, notably serving as the Head of Carticel French operations, focusing on autologous cartilage defects cell therapy.

In 2002, Christian embarked on his consulting venture, concentrating on orphan diseases. His expertise extends to advising a wide range of organizations, from research institutions and start-ups to industry giants and Venture Capital funds.

As a hands-on consultant, Christian is actively engaged in diverse projects ranging from company establishment to funding campaigns, asset monetization, licensing programs, regulatory strategies, and investment assessments.

With an educational background that includes Préparatoire HEC at Lycee Chaptal and graduate studies at ESCP Europe, Christian Girard is well-equipped to navigate the complexities of the life science and orphan drug industries.

Throughout his career, Christian has held prominent roles in various organizations, including Founder at ORPHAN DRUGS INDUSTRY Advisory & Intelligence, as well as serving in advisory capacities at Nekonal, VasoDynamics, I-Stem, overlord pharmaceuticals, Cascade Prodrug, Acer Therapeutics Inc., Karcinolys, Anagenesis Biotechnologies, Alliance4Growth (A4G), and www.biotech-intelligence.com. His early professional experiences include roles at Genzyme France and Deknatel Snowden Pencer.

Christian Girard's broad expertise, coupled with his wealth of experience across different sectors of the life science industry, positions him as a respected figure in the orphan drug landscape.